about
Complement in monoclonal antibody therapy of cancerChemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cp66Shc longevity protein regulates the proliferation of human ovarian cancer cellsp66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growthReactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cellsRituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.A novel role of Shc adaptor proteins in steroid hormone-regulated cancers.Revisiting histidine-dependent acid phosphatases: a distinct group of tyrosine phosphatases.Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells.An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients
P50
Q26860800-19AB46D4-E122-4EF7-938D-9DEC44B894C6Q30408922-80DDD546-8E80-49F0-805A-B8EB05263120Q33983890-75962DE7-6A90-442E-B365-413906086FA9Q34015848-40E6F384-847C-4685-8532-14BA39811907Q34025197-60B7CEDD-FE7D-4090-ABE0-66F6ACA186ECQ34273059-34414467-0E4F-4FA3-A2FC-D5F84B58F526Q35230227-1FF5A307-7EFE-4C91-936D-3C713BB8834AQ36328606-51CC1261-0ED3-4517-B109-3B3D48A2ADC8Q36959613-DFE4AEF0-186E-47F0-BB80-1888B1328CF6Q37323041-6FB10343-2966-45D2-952A-FAECAD091143Q37417021-5D6F1CD0-B0C2-4DD4-904B-D91A9519553CQ37419562-622CE6E3-32BE-4E82-9A13-06CC90E1635BQ40371697-4C596558-6790-4566-ACB7-FC72560B3164Q92429945-DB6D79E5-17BC-4CCF-AF52-5E4B2B498C8B
P50
description
investigador
@es
researcher
@en
name
Suresh Veeramani
@en
type
label
Suresh Veeramani
@en
prefLabel
Suresh Veeramani
@en
P108
P31
P496
0000-0001-9217-0872